Related Experiment Video
Updated: Jul 11, 2026
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
[Expression of human anti-HBsAg-interferon fusion protein in CHO cells]
Objective:
To study the possibility of expressing human anti-HBsAg-interferon fusion protein in CHO cells as a putative targeting drug for hepatitis B.
Methods:
Both the heavy and light chain genes of human anti-HBsAg antibody derived from a phage display library were fused with alpha-2b interferon (IFN-alpha-2b) gene in vitro by polymerase chain reaction. The IFN alpha-2b gene was placed at the C terminal and a 15 amino acid linker was introduced at the fusion site. The light chain-IFN expression plasmid pLIC was constructed with a mammalian expression vector pcDNA3.1(+) and the heavy chain-IFN expression plasmid pFID was constructed with another mammalian expression vector pCdhfr1. These plasmids and the anti-HBsAg full-length light and heavy chain expression plasmids (pLIC and pHFD, respectively) were transfected into CHO (dhfr-) cells by the following three combinations:I, pLIC + pHFD;II, pLIC + pFID; III, pLFC + pFID. The cultured supernatant of the transfected cells was collected and assayed for IFN activity and HBsAg affinity.
Results:
The supernatant of combination I and II displayed IFN activity but only combination I supernatant exhibited HBsAg affinity.
Conclusions:
The successful expression of a fusion protein with both HBsAg affinity and interferon activity may lead to a new way to make a targeting drug for hepatitis B.
